In addition, co-stimulatory domains such as CD28 or 4-1BB (CD137) can be added to improve CAR-T cells’ proliferation and survival rate in vivo, thus enhancing the anti-tumor activity of CAR-T cells (133, 134). Here, TNFRSF9 is linked to neoplasm.